Amid the spread of the pandemic, Convergency has announced the launch of a cloud-based technology platform to enable research processes to keep on going remotely.
With the acquisition of Weibel, SHL Medical looks to the development of novel drug delivery systems for self-administration, answering a need for improved patient-centricity in the sector.
Bold is on the hunt for supporters among the industry to help evaluate its investigational anti-cancer therapy as a potential coronavirus treatment, after seeing related elements.
TriNetX adapts its data platform to reflect the rising needs of the clinical research industry that works to fight the spread of the coronavirus pandemic with drug developments.
Windlas issued a warning letter by the US FDA after the regulator finds the manufacturer’s response inadequate to justify wrongdoings at its India facility.
Immunogenesis is tapping into ProBioGen’s manufacturing capabilities for its immuno-oncology lead candidate, as the potential treatment enters the clinic.
Nubilaria joins a wave of providers that is offering their services for free to researchers working on potential treatments for COVID-19, with its ACTide EDC web platform.
Biohaven’s drug for acute treatment of migraine, manufactured using Catalent’s Zydis technology for orally disintegrating tablets, receives approval from the US FDA.
Fujifilm Diosynth announced plans to build a research center in the UK to answer growing demand in services for biologics, vaccines, and gene therapies development.
A report by Science 37 examines key considerations for patient safety and business continuity in the clinical trial industry in light of the ongoing coronavirus pandemic.
Apprentice is sending sets of technology tools to pharmaceutical research and manufacturing facilities, including its Tandem AR collaboration platform.
Aiming to encourage entry of generic drugs on the market, the US FDA published a finalized guidance that regulates processes for relevant designations and expedited approvals.
Spaulding has been contracted by the US FDA to support clinical trials in various therapeutic areas for the following five years, starting with a $5m reward for the first year.
